Jiangsu Recbio Technology Co Ltd

02179

Company Profile

  • Business description

    Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.

  • Contact

    No. 888 Yaocheng Avenue
    Medical High-tech District
    Jiangsu Province
    Taizhou
    CHN

    T: +86 52388820888

    https://www.recbio.cn

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    531

Stocks News & Analysis

stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.
stocks

Morningstar analyst reacts to Macquarie Group’s earnings

Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks

Undervalued ASX share showing progress in global efforts

More clarity on the path forward in the UK.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,966.703.200.04%
CAC 407,857.3656.480.72%
DAX 4024,217.37247.011.03%
Dow JONES (US)44,632.99204.57-0.46%
FTSE 1009,136.3254.880.60%
HKSE25,524.4537.68-0.15%
NASDAQ21,098.2980.29-0.38%
Nikkei 22540,674.55323.72-0.79%
NZX 50 Index12,934.212.20-0.02%
S&P 5006,370.8618.91-0.30%
S&P/ASX 2008,704.606.900.08%
SSE Composite Index3,609.7111.770.33%

Market Movers